Tenaya Therapeutics Enters into Research Collaboration with Alnylam Pharmaceuticals to Identify and Validate Novel Genetic Targets for Cardiovascular Disease Therapeutics
Rhea-AI Summary
Tenaya Therapeutics (NASDAQ: TNYA) entered a research collaboration with Alnylam (NASDAQ: ALNY) on March 5, 2026 to identify and validate up to 15 gene targets for cardiovascular disease.
Tenaya will receive up to $10 million upfront plus reimbursed costs over a two-year validation term and may receive up to $1.13 billion in development and commercial milestone payments if targets lead to approved therapeutics; Alnylam will handle development and commercialization.
Positive
- Up to $10M upfront payment to Tenaya
- Validation of up to 15 gene targets across a two-year term
- Up to $1.13B in potential development and commercial milestone payments
- Alnylam assumes development and commercialization, reducing Tenaya's late-stage costs
Negative
- Milestone payments of $1.13B are contingent on approvals and are not guaranteed
- Tenaya's role limited to target validation; downstream value depends on Alnylam development success
- Validation term limited to two years, constraining timing for progress to development
News Market Reaction – TNYA
In the Mar 5 session, TNYA gained 40.92%, reflecting a significant positive market reaction. Argus tracked a peak move of +46.3% during that session. Our momentum scanner triggered 53 alerts that day, indicating high trading interest and price volatility. Trading volume was exceptionally heavy at 7.5x the daily average, suggesting very strong buying interest.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Mar 02 | Conference participation | Neutral | -3.5% | Upcoming Leerink Partners healthcare conference appearance and webcast details. |
| Jan 09 | Strategic update | Positive | -1.0% | Outlined 2026 priorities, clinical milestones and extended cash runway funding. |
| Dec 12 | Public offering priced | Negative | -37.5% | Large underwritten unit offering with warrants and stated development uses. |
| Dec 11 | Offering proposed | Negative | -37.5% | Announcement of intent to offer stock and warrants under Form S-3. |
| Dec 11 | Clinical hold lifted | Positive | -37.5% | FDA removed clinical hold on MyPEAK-1 Phase 1b/2a trial of TN-201. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Offerings have seen sharp negative reactions, while some positive clinical/strategic news has historically been met with muted or negative price moves.
Over the past few months, Tenaya navigated several material events. In Dec 2025, a proposed and then priced public offering with units and warrants coincided with a -37.5% move, highlighting sensitivity to dilution. A clinical hold removal for MyPEAK-1 (TN-201) the same day also saw a -37.5% reaction, showing limited reward for positive trial updates. In Jan 2026, strategic priorities and a funding update produced a modest -0.96% move. A Mar 2, 2026 conference appearance saw a -3.51% reaction.
Key Terms
rna interference medical
rnai therapeutics medical
gene targets medical
milestone payments financial
upfront payment financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
Agreement Combines Tenaya’s Expertise in Identification and Validation of
Genetic Heart Disease Targets with Alnylam’s Ability to Deliver Transformational Therapeutics
Tenaya to Receive Up to
SOUTH SAN FRANCISCO, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced a research collaboration agreement with Alnylam Pharmaceuticals (Nasdaq: ALNY), the leading RNAi therapeutics company, to discover novel human genetic targets for the potential development of disease-modifying treatments for cardiovascular diseases.
“This multi-target collaboration underscores Tenaya’s commitment to rigorous science and capitalizes on the proprietary capabilities that have contributed to the discovery and development of Tenaya’s pipeline of candidates for cardiovascular conditions,” said Faraz Ali, Chief Executive Officer of Tenaya Therapeutics. “By combining our modality agnostic target identification and validation capabilities with Alnylam’s leadership in RNA interference therapeutics, we have an opportunity to advance candidates for novel genetic targets with the potential to create transformational medicines for patients with heart disease.”
Under the terms of the agreement, Tenaya Therapeutics will validate up to 15 gene targets. Tenaya will receive up to
About Tenaya’s Target Identification and Validation Capabilities
Tenaya has established a diverse portfolio of proprietary integrated capabilities to enable modality agnostic target identification and validation anchored in human genetics. These capabilities encompass the use of human induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) with high throughput in vitro screening, imaging analysis and machine learning algorithms to identify novel genetic targets, and human engineered heart tissue and preclinical in vivo models of human disease to validate and characterize potential product candidates. Collectively, Tenaya’s target identification and validation capabilities have generated more than 150 genetic targets and contributed to the discovery and development of the company’s clinical-stage candidates, including the TN-201 and TN-401 gene therapies and TN-301 small molecule, as well as diverse early-stage programs.
About Tenaya Therapeutics
Tenaya Therapeutics is a clinical-stage biotechnology company committed to a bold mission: to discover, develop and deliver potentially curative therapies that address the underlying drivers of heart disease. Tenaya’s pipeline includes clinical-stage candidates TN-201, a gene therapy for MYBPC3-associated hypertrophic cardiomyopathy (HCM) and TN-401, a gene therapy for PKP2-associated arrhythmogenic right ventricular cardiomyopathy (ARVC). Tenaya has employed a suite of integrated internal capabilities, including modality agnostic target validation, capsid engineering and manufacturing, to generate a portfolio of novel medicines based on genetic insights, including TN-301, a clinical-stage small molecule HDAC6 inhibitor for the potential treatment of heart failure and related cardio/muscular disease, and multiple early-stage programs in preclinical development aimed at the treatment of both rare genetic disorders and more prevalent heart conditions. For more information, visit www.tenayatherapeutics.com.
Forward Looking Statements
This press release contains forward-looking statements as that term is defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this press release that are not purely historical are forward-looking statements. Words such as “commitment,” “opportunity,” “potential,” “will,” and “may,” and similar expressions are intended to identify forward-looking statements. Such forward-looking statements include, among other things, Tenaya’s commitment to rigorous science; the opportunity to advance candidates for novel genetic targets and potential to create transformational medicines for patients with heart disease under the collaboration; the potential for Tenaya to receive upfront, development and commercial milestone payments, as well as research reimbursement under the collaboration; and statements made by Tenaya’s Chief Executive Officer. The forward-looking statements contained herein are based upon Tenaya’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. These forward-looking statements are neither promises nor guarantees and are subject to a variety of risks and uncertainties, including but not limited to: Tenaya’s ability to achieve the expected benefits from the collaboration; risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics; Tenaya’s continuing compliance with applicable legal and regulatory requirements; Tenaya’s ability to raise any additional funding it will need to continue to execute on its business plans, including performing its obligations under the collaboration with Alnylam; unanticipated early termination of the collaboration with Alnylam; Tenaya’s reliance on third parties; Tenaya’s research capabilities and strategy; the loss of key scientific or management personnel; Tenaya’s ability to obtain and maintain intellectual property protection for its platform technology and product candidates; general economic and market conditions; and other risks. Information regarding the foregoing and additional risks may be found in the section titled “Risk Factors” in Tenaya’s Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2025, and other documents that Tenaya files from time to time with the Securities and Exchange Commission. These forward-looking statements are made as of the date of this press release, and Tenaya assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Tenaya Contacts
Michelle Corral
VP, Corporate Communications and Investor Relations
IR@tenayathera.com
Investors
Anne-Marie Fields
Precision AQ
annemarie.fields@precisionaq.com
Media
Wendy Ryan
Ten Bridge Communications
wendy@tenbridgecommunications.com
